Cart
sales@molnova.com
Byakangelicol
CAS No. 26091-79-2
Byakangelicol( —— )
Catalog No. M18325 CAS No. 26091-79-2
Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 136 | In Stock |
|
| 5MG | 128 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 330 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameByakangelicol
-
NoteResearch use only, not for human use.
-
Brief DescriptionByakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions.
-
DescriptionByakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions. Byakangelicol can inhibit IL-1beta-induced PGE2 release in A549 cells; this inhibition may be mediated by suppression of COX-2 expression and the activity of COX-2 enzyme, thus it may have therapeutic potential as an anti-inflammatory drug on airway inflammation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorCOX-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number26091-79-2
-
Formula Weight316.3
-
Molecular FormulaC17H16O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (158.07 mM)
-
SMILESCC1(C(O1)COC2=C3C(=C(C4=C2OC(=O)C=C4)OC)C=CO3)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
DEL-22379
A small molecule inhibitor of ERK dimerization with IC50 of 0.5 uM, without affecting ERK phosphorylation.
-
BIX02188 (c)
BIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM.
-
Asperulosidic acid
Asperulosidic acid has anti-tumor, anti-oxidant, and anti-inflammatory activities.ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways.
